Mohamed Ismail Nounou
Appalachian College of Pharmacy, USA
Title: Novel bioconjugate carriers as drugs ver. 3.0: Design language, merits and bench to bedside transformation
Biography
Biography: Mohamed Ismail Nounou
Abstract
Observing the research and development for novel and innovative drug carrier systems in the past fifteen years has been thrilling and exciting. The research trend moving from prodrug technologies based on minimal chemical modifications to comply to Lipiniski rule of five (Drugs Ver 1.0), to novel nanocarriers such as nanoparticles, nanoemulsaions, vesicular systems and polymeric and peptidomemetic systems (Drugs Ver 2.0) to finally novel bioresponsive smart bioconjugates (Drugs Ver 3.0). This review would focus on novel smart bioconjugates, current innovations in its design language, advantages, industrialization, scaling-up, current patent status and its transformation from bench (Lab. small scale production) to bedside (industrial manufacturing stage). Finally, this review will focus on the role of pharmaceutical formulators in transitioning novel bioconjugates from synthetic chemical compounds to final dosage forms, overcoming the hurdles of synthesis reproducibility and purity of the final bioconjugates and the associated adjuvants used in the chemical synthesis. Innovative and updated strategies in formulation design and development are required to take bioconjugate systems efficiently from bench to bedside.